
IDYA Stock Forecast & Price Target
IDYA Analyst Ratings
Bulls say
IDEAYA Biosciences is quickly advancing their lead drug candidate, IDE849, through clinical trials, with data reported from the Hengrui-sponsored China study and initial data set to be reported from their own Phase 1 study later this year. The company has promising efficacy data for IDE849, showing a potential best-in-class profile in treating relapsed/refractory ES-SCLC and epNEC, with response rates and progression-free survival estimates exceeding those of competing ADCs. They have also received positive feedback from the FDA regarding their Phase 3 study design, and their recent offering has bolstered their financial position for future growth.
Bears say
IDEAYA Biosciences is facing significant competition in the market for its oncology-focused precision medicine products, and its clinical-stage product candidates have only reached the Phase 1 stage, with potentially more risk and uncertainty in their outcomes. With projected sales estimates for peak revenue being adjusted and a low upside potential compared to downside risk, the current market price is overvalued. Additionally, with a limited portfolio of only a few product candidates, IDEAYA may face challenges in diversifying its revenue streams and achieving sustainable growth.
This aggregate rating is based on analysts' research of Ideaya Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.
IDYA Analyst Forecast & Price Prediction
Start investing in IDYA
Order type
Buy in
Order amount
Est. shares
0 shares